CGT4HIVCure 2015

Anti-HIV-1 shRNAs protect CD8+ T cells modified with CD4ζ CAR from HIV-1 infection and impairment of cell proliferation

Masakazu Kamata, Ph.D.

Division of Hematology-Oncology, David Geffen School of Medicine at UCLA
Summary for Community

1. Key question of research
   → What do we need to achieve for a successful CAR-based anti-HIV-1 therapy? (CAR design, Carrier vehicle)

2. Key finding and take home message
   → Protecting CAR-modified T cells from HIV-1 infection is required for efficient HIV-1-specific immune surveillance.

3. Why is this important? How is this related to a cure?
   → The potential of CAR-based therapies can be effective if HIV-1 susceptibility is addressed.

4. Why should we not be excited about this yet?
   → Establishing antigen-specific immunological memory may be a key requirement for long-lived resistance to HIV-1.